[English] 日本語
Yorodumi
- EMDB-52997: HER2/ErbB2 extracellular domain (ECD) in compact conformation in ... -

+
Open data


ID or keywords:

Loading...

-
Basic information

Entry
Database: EMDB / ID: EMD-52997
TitleHER2/ErbB2 extracellular domain (ECD) in compact conformation in complex with trastuzumab (TZB) antibody
Map dataFull map from focused refinement, used for model validation
Sample
  • Complex: Ternary complex of HER2/ErbB2 in compact conformation with trastuzumab (TZB) antibody.
    • Protein or peptide: Receptor tyrosine-protein kinase erbB-2,Green fluorescent protein
KeywordsReceptor / tyrosine kinase / transmembrane / HER2 / SIGNALING PROTEIN
Function / homology
Function and homology information


negative regulation of immature T cell proliferation in thymus / ERBB3:ERBB2 complex / ERBB2-ERBB4 signaling pathway / GRB7 events in ERBB2 signaling / immature T cell proliferation in thymus / RNA polymerase I core binding / semaphorin receptor complex / regulation of microtubule-based process / ErbB-3 class receptor binding / motor neuron axon guidance ...negative regulation of immature T cell proliferation in thymus / ERBB3:ERBB2 complex / ERBB2-ERBB4 signaling pathway / GRB7 events in ERBB2 signaling / immature T cell proliferation in thymus / RNA polymerase I core binding / semaphorin receptor complex / regulation of microtubule-based process / ErbB-3 class receptor binding / motor neuron axon guidance / Sema4D induced cell migration and growth-cone collapse / PLCG1 events in ERBB2 signaling / ERBB2-EGFR signaling pathway / neurotransmitter receptor localization to postsynaptic specialization membrane / ERBB2 Activates PTK6 Signaling / enzyme-linked receptor protein signaling pathway / neuromuscular junction development / ERBB2-ERBB3 signaling pathway / positive regulation of Rho protein signal transduction / Drug-mediated inhibition of ERBB2 signaling / Resistance of ERBB2 KD mutants to trastuzumab / Resistance of ERBB2 KD mutants to sapitinib / Resistance of ERBB2 KD mutants to tesevatinib / Resistance of ERBB2 KD mutants to neratinib / Resistance of ERBB2 KD mutants to osimertinib / Resistance of ERBB2 KD mutants to afatinib / Resistance of ERBB2 KD mutants to AEE788 / Resistance of ERBB2 KD mutants to lapatinib / Drug resistance in ERBB2 TMD/JMD mutants / positive regulation of transcription by RNA polymerase I / ERBB2 Regulates Cell Motility / oligodendrocyte differentiation / semaphorin-plexin signaling pathway / PI3K events in ERBB2 signaling / positive regulation of protein targeting to membrane / regulation of angiogenesis / positive regulation of MAP kinase activity / regulation of ERK1 and ERK2 cascade / Schwann cell development / Downregulation of ERBB2:ERBB3 signaling / coreceptor activity / Signaling by ERBB2 / TFAP2 (AP-2) family regulates transcription of growth factors and their receptors / myelination / transmembrane receptor protein tyrosine kinase activity / GRB2 events in ERBB2 signaling / positive regulation of cell adhesion / SHC1 events in ERBB2 signaling / basal plasma membrane / cell surface receptor protein tyrosine kinase signaling pathway / Constitutive Signaling by Overexpressed ERBB2 / cellular response to epidermal growth factor stimulus / positive regulation of epithelial cell proliferation / bioluminescence / positive regulation of translation / generation of precursor metabolites and energy / phosphatidylinositol 3-kinase/protein kinase B signal transduction / wound healing / peptidyl-tyrosine phosphorylation / Signaling by ERBB2 TMD/JMD mutants / Downregulation of ERBB2 signaling / receptor protein-tyrosine kinase / Signaling by ERBB2 ECD mutants / receptor tyrosine kinase binding / Signaling by ERBB2 KD Mutants / neuromuscular junction / cellular response to growth factor stimulus / ruffle membrane / epidermal growth factor receptor signaling pathway / neuron differentiation / Constitutive Signaling by Aberrant PI3K in Cancer / transmembrane signaling receptor activity / PIP3 activates AKT signaling / myelin sheath / heart development / presynaptic membrane / RAF/MAP kinase cascade / PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling / positive regulation of cell growth / protein tyrosine kinase activity / basolateral plasma membrane / early endosome / cell surface receptor signaling pathway / cell population proliferation / endosome membrane / receptor complex / positive regulation of MAPK cascade / intracellular signal transduction / protein phosphorylation / apical plasma membrane / protein heterodimerization activity / signaling receptor binding / negative regulation of apoptotic process / perinuclear region of cytoplasm / signal transduction / nucleoplasm / ATP binding / identical protein binding / nucleus / membrane
Similarity search - Function
: / Epidermal growth factor receptor transmembrane-juxtamembrane segment / Tyrosine protein kinase, EGF/ERB/XmrK receptor / Growth factor receptor domain 4 / Growth factor receptor domain IV / Receptor L-domain / Furin-like cysteine-rich domain / Receptor L-domain superfamily / Furin-like cysteine rich region / Receptor L domain ...: / Epidermal growth factor receptor transmembrane-juxtamembrane segment / Tyrosine protein kinase, EGF/ERB/XmrK receptor / Growth factor receptor domain 4 / Growth factor receptor domain IV / Receptor L-domain / Furin-like cysteine-rich domain / Receptor L-domain superfamily / Furin-like cysteine rich region / Receptor L domain / Furin-like repeat / Furin-like repeats / Green fluorescent protein, GFP / Green fluorescent protein-related / Green fluorescent protein / Green fluorescent protein / Growth factor receptor cysteine-rich domain superfamily / : / Tyrosine-protein kinase, catalytic domain / Tyrosine kinase, catalytic domain / Tyrosine protein kinases specific active-site signature. / Tyrosine-protein kinase, active site / Serine-threonine/tyrosine-protein kinase, catalytic domain / Protein tyrosine and serine/threonine kinase / Protein kinase, ATP binding site / Protein kinases ATP-binding region signature. / Protein kinase domain profile. / Protein kinase domain / Protein kinase-like domain superfamily
Similarity search - Domain/homology
Receptor tyrosine-protein kinase erbB-2 / Green fluorescent protein
Similarity search - Component
Biological speciesHomo sapiens (human) / Aequorea victoria (jellyfish)
Methodsingle particle reconstruction / cryo EM / Resolution: 3.8 Å
AuthorsGragera M / Buschiazzo A / Vacca S
Funding supportEuropean Union, 1 items
OrganizationGrant numberCountry
European Research Council (ERC)HighResCells (ERC-2018-SyG, Proposal 810057)European Union
CitationJournal: Sci Adv / Year: 2025
Title: Structural analysis of HER2-trastuzumab complex reveals receptor conformational adaptation.
Authors: Santiago Vacca / Marcos Gragera / Alejandro Buschiazzo / David Herreros / James M Krieger / Santiago Bonn-Garcia / Roberto Melero / Carlos Os Sorzano / Jose M Carazo / Ohad Medalia / Andreas Plückthun /
Abstract: Human epidermal growth factor receptor-2 (HER2) is a receptor tyrosine kinase, associated with a variety of malignant tumors, usually through overexpression, resulting in aberrant signaling. ...Human epidermal growth factor receptor-2 (HER2) is a receptor tyrosine kinase, associated with a variety of malignant tumors, usually through overexpression, resulting in aberrant signaling. Trastuzumab (TZB), one of the monoclonal antibodies (mAbs) used in combination with chemotherapy, has become a major therapeutic for HER2-overexpressing cancers. Current structural understanding of HER2 and its interactions with other receptors and with different affinity agents has relied on numerous structures of individual domains of HER2. Here, we subjected purified near full-length HER2 to single-particle cryo-electron microscopy (cryo-EM) analysis. Besides the canonical conformation described in previous structural studies, we report a previously unreported conformation of the HER2 extracellular domain that is stabilized upon TZB binding, which might hamper association with HER3, a receptor with which HER2 forms an oncogenic unit. Together, our findings provide insights into the conformational dynamics of the HER2 receptor and the mechanism of action of TZB.
History
DepositionMar 2, 2025-
Header (metadata) releaseAug 6, 2025-
Map releaseAug 6, 2025-
UpdateAug 6, 2025-
Current statusAug 6, 2025Processing site: PDBe / Status: Released

-
Structure visualization

Supplemental images

emd_52997.png

Downloads & links

-
Map

FileDownload / File: emd_52997.map.gz / Format: CCP4 / Size: 30.5 MB / Type: IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES)
AnnotationFull map from focused refinement, used for model validation
Projections & slices

Image control

Size
Brightness
Contrast
Others
AxesZ (Sec.)Y (Row.)X (Col.)
1.3 Å/pix.
x 200 pix.
= 260.4 Å		1.3 Å/pix.
x 200 pix.
= 260.4 Å		1.3 Å/pix.
x 200 pix.
= 260.4 Å

Surface

Projections

Slices (1/3)

Slices (1/2)

Slices (2/3)

Images are generated by Spider.

Voxel sizeX=Y=Z: 1.302 Å
Density

Histogram

Histogram (log scale)
Contour LevelBy AUTHOR: 0.25
Minimum - Maximum-0.65776473 - 2.0645266
Average (Standard dev.)-0.00088613847 (±0.045050103)
SymmetrySpace group: 1
Details

EMDB XML:

Map geometry
Axis orderXYZ
Origin000
Dimensions200200200
Spacing200200200
CellA=B=C: 260.40002 Å
α=β=γ: 90.0 °

-
Supplemental data

+
Mask #1

Fileemd_52997_msk_1.map
Projections & Slices
AxesZYX

Projections

Slices (1/2)
Density Histograms

Histogram

Histogram (log scale)

+
Additional map: Sharpened map with deepEMhancer.

Fileemd_52997_additional_1.map
AnnotationSharpened map with deepEMhancer.
Projections & Slices
AxesZYX

Projections

Slices (1/2)
Density Histograms

Histogram

Histogram (log scale)

+
Additional map: Full map of the unmasked refinement.

Fileemd_52997_additional_2.map
AnnotationFull map of the unmasked refinement.
Projections & Slices
AxesZYX

Projections

Slices (1/2)
Density Histograms

Histogram

Histogram (log scale)

+
Additional map: Half map of the unmasked refinement.

Fileemd_52997_additional_3.map
AnnotationHalf map of the unmasked refinement.
Projections & Slices
AxesZYX

Projections

Slices (1/2)
Density Histograms

Histogram

Histogram (log scale)

+
Additional map: Half map of the unmasked refinement.

Fileemd_52997_additional_4.map
AnnotationHalf map of the unmasked refinement.
Projections & Slices
AxesZYX

Projections

Slices (1/2)
Density Histograms

Histogram

Histogram (log scale)

+
Additional map: Sharpened map with relion post-processing.

Fileemd_52997_additional_5.map
AnnotationSharpened map with relion post-processing.
Projections & Slices
AxesZYX

Projections

Slices (1/2)
Density Histograms

Histogram

Histogram (log scale)

+
Additional map: Half map from focused refinement, low pass-filtered at 4.5 Angstroms.

Fileemd_52997_additional_6.map
AnnotationHalf map from focused refinement, low pass-filtered at 4.5 Angstroms.
Projections & Slices
AxesZYX

Projections

Slices (1/2)
Density Histograms

Histogram

Histogram (log scale)

+
Additional map: Full map from focused refinement, low pass-filtered at 4.5 Angstroms.

Fileemd_52997_additional_7.map
AnnotationFull map from focused refinement, low pass-filtered at 4.5 Angstroms.
Projections & Slices
AxesZYX

Projections

Slices (1/2)
Density Histograms

Histogram

Histogram (log scale)

+
Additional map: Half map from focused refinement, low pass-filtered at 4.5 Angstroms.

Fileemd_52997_additional_8.map
AnnotationHalf map from focused refinement, low pass-filtered at 4.5 Angstroms.
Projections & Slices
AxesZYX

Projections

Slices (1/2)
Density Histograms

Histogram

Histogram (log scale)

+
Additional map: Sharpened map with deepEMhancer, low pass-filtered at 4.5 Angstroms.

Fileemd_52997_additional_9.map
AnnotationSharpened map with deepEMhancer, low pass-filtered at 4.5 Angstroms.
Projections & Slices
AxesZYX

Projections

Slices (1/2)
Density Histograms

Histogram

Histogram (log scale)

+
Half map: #2

Fileemd_52997_half_map_1.map
Projections & Slices
AxesZYX

Projections

Slices (1/2)
Density Histograms

Histogram

Histogram (log scale)

+
Half map: #1

Fileemd_52997_half_map_2.map
Projections & Slices
AxesZYX

Projections

Slices (1/2)
Density Histograms

Histogram

Histogram (log scale)

-
Sample components

-
Entire : Ternary complex of HER2/ErbB2 in compact conformation with trastu...

EntireName: Ternary complex of HER2/ErbB2 in compact conformation with trastuzumab (TZB) antibody.
Components
  • Complex: Ternary complex of HER2/ErbB2 in compact conformation with trastuzumab (TZB) antibody.
    • Protein or peptide: Receptor tyrosine-protein kinase erbB-2,Green fluorescent protein

-
Supramolecule #1: Ternary complex of HER2/ErbB2 in compact conformation with trastu...

SupramoleculeName: Ternary complex of HER2/ErbB2 in compact conformation with trastuzumab (TZB) antibody.
type: complex / ID: 1 / Parent: 0 / Macromolecule list: all
Details: Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD.
Source (natural)Organism: Homo sapiens (human)
Molecular weightTheoretical: 112 KDa

-
Macromolecule #1: Receptor tyrosine-protein kinase erbB-2,Green fluorescent protein

MacromoleculeName: Receptor tyrosine-protein kinase erbB-2,Green fluorescent protein
type: protein_or_peptide / ID: 1
Details: Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 ...Details: Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.,Near-full length HER2/ErbB2 in complex with full length humanized monoclonal antibody trastuzumab (TZB). The final reconstruction contains only the HER2 ECD head.
Number of copies: 1 / Enantiomer: LEVO / EC number: receptor protein-tyrosine kinase
Source (natural)Organism: Aequorea victoria (jellyfish)
Molecular weightTheoretical: 146.737172 KDa
Recombinant expressionOrganism: Spodoptera frugiperda (fall armyworm)
SequenceString: MKFLVNVALV FMVVYISYIY ADYKDDDDKH HHHHHHHHHL EVLFQGPYPY DVPDYATQVC TGTDMKLRLP ASPETHLDML RHLYQGCQV VQGNLELTYL PTNASLSFLQ DIQEVQGYVL IAHNQVRQVP LQRLRIVRGT QLFEDNYALA VLDNGDPLNN T TPVTGASP ...String:
MKFLVNVALV FMVVYISYIY ADYKDDDDKH HHHHHHHHHL EVLFQGPYPY DVPDYATQVC TGTDMKLRLP ASPETHLDML RHLYQGCQV VQGNLELTYL PTNASLSFLQ DIQEVQGYVL IAHNQVRQVP LQRLRIVRGT QLFEDNYALA VLDNGDPLNN T TPVTGASP GGLRELQLRS LTEILKGGVL IQRNPQLCYQ DTILWKDIFH KNNQLALTLI DTNRSRACHP CSPMCKGSRC WG ESSEDCQ SLTRTVCAGG CARCKGPLPT DCCHEQCAAG CTGPKHSDCL ACLHFNHSGI CELHCPALVT YNTDTFESMP NPE GRYTFG ASCVTACPYN YLSTDVGSCT LVCPLHNQEV TAEDGTQRCE KCSKPCARVC YGLGMEHLRE VRAVTSANIQ EFAG CKKIF GSLAFLPESF DGDPASNTAP LQPEQLQVFE TLEEITGYLY ISAWPDSLPD LSVFQNLQVI RGRILHNGAY SLTLQ GLGI SWLGLRSLRE LGSGLALIHH NTHLCFVHTV PWDQLFRNPH QALLHTANRP EDECVGEGLA CHQLCARGHC WGPGPT QCV NCSQFLRGQE CVEECRVLQG LPREYVNARH CLPCHPECQP QNGSVTCFGP EADQCVACAH YKDPPFCVAR CPSGVKP DL SYMPIWKFPD EEGACQPCPI NCTHSCVDLD DKGCPAEQRA SPLTSIISAV VGILLVVVLG VVFGILIKRR QQKIRKYT M RRLLQETELV EPLTPSGAMP NQAQMRILKE TELRKVKVLG SGAFGTVYKG IWIPDGENVK IPVAIKVLRE NTSPKANKE ILDEAYVMAG VGSPYVSRLL GISLTSTVQL VTQLMPYGSL LDHVRENRGR LGSQDLLNWC MQIAKGMSYL EDVRLVHRDL AARNVLVKS PNHVKITDFG LARLLDIDET EYHADGGKVP IKWMALESIL RRRFTHQSDV WSYGVTVWEL MTFGAKPYDG I PAREIPDL LEKGERLPQP PICTIDVYMI MVKCWMIDSE SRPRFRELVS EFSRMARDPQ RFVVIQNEDL GPASPLDSTF YR SLLEDDD MGDLVDAEEY LVPQQGLEVL FQGPGSMSKG EELFTGVVPI LVELDGDVNG HKFSVRGEGE GDATNGKLTL KFI CTTGKL PVPWPTLVTT LTYGVQCFSR YPDHMKRHDF FKSAMPEGYV QERTISFKDD GTYKTRAEVK FEGDTLVNRI ELKG IDFKE DGNILGHKLE YNFNSHNVYI TADKQKNGIK ANFKIRHNVE DGSVQLADHY QQNTPIGDGP VLLPDNHYLS TQSVL SKDP NEKRDHMVLL EFVTAAGITH GMDELYK

UniProtKB: Receptor tyrosine-protein kinase erbB-2, Green fluorescent protein

-
Experimental details

-
Structure determination

Methodcryo EM
Processingsingle particle reconstruction
Aggregation stateparticle

-
Sample preparation

BufferpH: 7.5
GridModel: Quantifoil R1.2/1.3 / Material: GOLD / Mesh: 200 / Support film - Material: CARBON / Support film - topology: HOLEY / Pretreatment - Type: GLOW DISCHARGE
VitrificationCryogen name: ETHANE / Chamber humidity: 100 % / Chamber temperature: 277.15 K / Instrument: FEI VITROBOT MARK IV

-
Electron microscopy

MicroscopeTFS KRIOS
Specialist opticsEnergy filter - Name: GIF Bioquantum / Energy filter - Slit width: 20 eV
Image recordingFilm or detector model: GATAN K3 BIOQUANTUM (6k x 4k) / Number grids imaged: 2 / Number real images: 24624 / Average exposure time: 1.2 sec. / Average electron dose: 72.3 e/Å2
Details: Two grids imaged: - Grid 1: 5428 movies. - Grid 2: 19196 movies.
Electron beamAcceleration voltage: 300 kV / Electron source: FIELD EMISSION GUN
Electron opticsIllumination mode: FLOOD BEAM / Imaging mode: BRIGHT FIELD / Cs: 2.7 mm / Nominal defocus max: 2.4 µm / Nominal defocus min: 0.8 µm / Nominal magnification: 130000
Sample stageSpecimen holder model: FEI TITAN KRIOS AUTOGRID HOLDER / Cooling holder cryogen: NITROGEN
Experimental equipment
Model: Titan Krios / Image courtesy: FEI Company

+
Image processing

Particle selectionNumber selected: 4207722
CTF correctionType: PHASE FLIPPING AND AMPLITUDE CORRECTION
Startup modelType of model: INSILICO MODEL
In silico model: Ab-initio reconstruction from experimental particles using cryoSPARC v3.2
Final reconstructionApplied symmetry - Point group: C1 (asymmetric) / Resolution.type: BY AUTHOR / Resolution: 3.8 Å / Resolution method: FSC 0.143 CUT-OFF / Number images used: 91370
Initial angle assignmentType: MAXIMUM LIKELIHOOD
Final angle assignmentType: MAXIMUM LIKELIHOOD / Software - Name: cryoSPARC (ver. 4.4) / Details: CryoSPARC v4.4
Final 3D classificationNumber classes: 4
FSC plot (resolution estimation)

-
Atomic model buiding 1

Initial modelPDB ID:

5my6


Chain - Source name: PDB / Chain - Initial model type: experimental model
RefinementSpace: REAL / Protocol: RIGID BODY FIT / Target criteria: Cross-correlation coefficient
Output model

PDB-9qbf:
HER2/ErbB2 extracellular domain (ECD) in compact conformation in complex with trastuzumab (TZB) antibody

+
About Yorodumi

-
News

-
Feb 9, 2022. New format data for meta-information of EMDB entries

New format data for meta-information of EMDB entries

  • Version 3 of the EMDB header file is now the official format.
  • The previous official version 1.9 will be removed from the archive.

Related info.:EMDB header

External links:wwPDB to switch to version 3 of the EMDB data model

-
Aug 12, 2020. Covid-19 info

Covid-19 info

URL: https://pdbj.org/emnavi/covid19.php

New page: Covid-19 featured information page in EM Navigator.

Related info.:Covid-19 info / Mar 5, 2020. Novel coronavirus structure data

+
Mar 5, 2020. Novel coronavirus structure data

Novel coronavirus structure data

Related info.:Yorodumi Speices / Aug 12, 2020. Covid-19 info

External links:COVID-19 featured content - PDBj / Molecule of the Month (242)：Coronavirus Proteases

+
Jan 31, 2019. EMDB accession codes are about to change! (news from PDBe EMDB page)

EMDB accession codes are about to change! (news from PDBe EMDB page)

  • The allocation of 4 digits for EMDB accession codes will soon come to an end. Whilst these codes will remain in use, new EMDB accession codes will include an additional digit and will expand incrementally as the available range of codes is exhausted. The current 4-digit format prefixed with “EMD-” (i.e. EMD-XXXX) will advance to a 5-digit format (i.e. EMD-XXXXX), and so on. It is currently estimated that the 4-digit codes will be depleted around Spring 2019, at which point the 5-digit format will come into force.
  • The EM Navigator/Yorodumi systems omit the EMD- prefix.

Related info.:Q: What is EMD? / ID/Accession-code notation in Yorodumi/EM Navigator

External links:EMDB Accession Codes are Changing Soon! / Contact to PDBj

+
Jul 12, 2017. Major update of PDB

Major update of PDB

  • wwPDB released updated PDB data conforming to the new PDBx/mmCIF dictionary.
  • This is a major update changing the version number from 4 to 5, and with Remediation, in which all the entries are updated.
  • In this update, many items about electron microscopy experimental information are reorganized (e.g. em_software).
  • Now, EM Navigator and Yorodumi are based on the updated data.

External links:wwPDB Remediation / Enriched Model Files Conforming to OneDep Data Standards Now Available in the PDB FTP Archive

-
Yorodumi

Thousand views of thousand structures

  • Yorodumi is a browser for structure data from EMDB, PDB, SASBDB, etc.
  • This page is also the successor to EM Navigator detail page, and also detail information page/front-end page for Omokage search.
  • The word "yorodu" (or yorozu) is an old Japanese word meaning "ten thousand". "mi" (miru) is to see.

Related info.:EMDB / PDB / SASBDB / Comparison of 3 databanks / Yorodumi Search / Aug 31, 2016. New EM Navigator & Yorodumi / Yorodumi Papers / Jmol/JSmol / Function and homology information / Changes in new EM Navigator and Yorodumi

Read more